drugset / Trial / NCT04116528

Opiate Suicide Study in Patients With Major Depression

NCT04116528

Phase 3 Completed 50 enrolled Stanford University
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To explore whether intravenous ketamine followed by buprenorphine produces more rapid and sustained anti-suicidal effects than ketamine followed by placebo, investigators will conduct a single study that will take approximately 2.5 years to complete. 60 subjects (60 infusions) or approximately 24 infusions per year.

Timeline

Start
2020-08-01
Primary completion
2025-04-28
Completion
2025-04-28

Drugs

EvaluationDrugModalityDoseRoute
Comparator Buprenorphine Other / unclassified 0.2 mg Other
Comparator Buprenorphine Other / unclassified 0.8 mg Other